A statement of the Committee of the Czech Society for Atherosclerosis on the 2019 ESC/EAS guidelines for the diagnosis and treatment of dyslipidemia
Abstract
In August 2019, a new version of guidelines for the diagnosis and treatment of dyslipidemia was published by authors representing the European Cardiology Society (ESC) and the European Society for Atherosclerosis (EAS) [1]. Again, it is a complex and extensive material that can be considered as a reference - it revises the evidence on which we base diagnostic and therapeutic procedures, but given the extent and complexity of the material, we are unlikely to use it in daily practice.
The Committee of the Czech Society for Atherosclerosis (ČSAT) prepared the following opinion as a summary of the most important and significant changes that differ from the previous ESC / EAS Guidelines of 2016 and the CSAT Opinion on these Guidelines published in 2017 [2,3]. The ČSAT Committee considers ESC / EAS 2019 recommendations for the management of dyslipidemia also suitable for health care in the Czech Republic.
The opinion does not replace the commented recommendations and we recommend that the full text be read for detailed text. When comparing the current and previous ČSAT Opinion of 2017, the general rules of evaluation of evidence for recommending individual interventions and the wording that follow from them remain valid (recommended, to be considered, may be considered under certain circumstances, not recommended); however, the present opinion comments on important changes, including a tabular summary of the news.